A multifunctional therapy approach for cancer: Targeting Raf1- Mediated inhibition of cell motility, growth, and interaction with the microenvironment

Limin Zhang, Abhinandan Pattanayak, Wenqi Li, Hyun Kyung Ko, Graham Fowler, Ryan Gordon, Raymond Bergan

Research output: Contribution to journalArticle

Abstract

Prostate cancer cells move from their primary site of origin, interact with a distant microenvironment, grow, and thereby cause death. It had heretofore not been possible to selectively inhibit cancer cell motility. Our group has recently shown that inhibition of intracellular activation of Raf1 with the small-molecule therapeutic KBU2046 permits, for the first time, selective inhibition of cell motility. We hypothesized that simultaneous disruption of multiple distinct functions that drive progression of prostate cancer to induce death would result in advanced disease control. Using a murine orthotopic implantation model of human prostate cancer metastasis, we demonstrate that combined treatment with KBU2046 and docetaxel retains docetaxel's antitumor action, but provides improved inhibition of metastasis, compared with monotherapy. KBU2046 does not interfere with hormone therapy, inclusive of enzalutamide-mediated inhibition of androgen receptor (AR) function and cell growth inhibition, and inclusive of the ability of castration to inhibit LNCaP-AR cell outgrowth in mice. Cell movement is necessary for osteoclast-mediated bone degradation. KBU2046 inhibits Raf1 and its downstream activation of MEK1/2 and ERK1/2 in osteoclasts, inhibiting cytoskeleton rearrangement, resorptive cavity formation, and bone destruction in vitro, with improved effects observed when the bone microenvironment is chemically modified by pretreatment with zoledronic acid. Using a murine cardiac injection model of human prostate cancer bone destruction quantified by CT, KBU2046 plus zoledronic exhibit improved inhibitory efficacy, compared with monotherapy. The combined disruption of pathways that drive cell movement, interaction with bone, and growth constitutes a multifunctional targeting strategy that provides advanced disease control.

Original languageEnglish (US)
Pages (from-to)39-51
Number of pages13
JournalMolecular cancer therapeutics
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2020

Fingerprint

docetaxel
Cell Communication
Cell Movement
Prostatic Neoplasms
zoledronic acid
Androgen Receptors
Osteoclasts
Growth
Neoplasms
Neoplasm Metastasis
Bone and Bones
Bone Neoplasms
Castration
Bone Development
Therapeutics
Cytoskeleton
Osteogenesis
Cause of Death
Hormones
Injections

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A multifunctional therapy approach for cancer : Targeting Raf1- Mediated inhibition of cell motility, growth, and interaction with the microenvironment. / Zhang, Limin; Pattanayak, Abhinandan; Li, Wenqi; Ko, Hyun Kyung; Fowler, Graham; Gordon, Ryan; Bergan, Raymond.

In: Molecular cancer therapeutics, Vol. 19, No. 1, 01.01.2020, p. 39-51.

Research output: Contribution to journalArticle

Zhang, Limin ; Pattanayak, Abhinandan ; Li, Wenqi ; Ko, Hyun Kyung ; Fowler, Graham ; Gordon, Ryan ; Bergan, Raymond. / A multifunctional therapy approach for cancer : Targeting Raf1- Mediated inhibition of cell motility, growth, and interaction with the microenvironment. In: Molecular cancer therapeutics. 2020 ; Vol. 19, No. 1. pp. 39-51.
@article{d7f077e9c12147d38a119f45fbcc9258,
title = "A multifunctional therapy approach for cancer: Targeting Raf1- Mediated inhibition of cell motility, growth, and interaction with the microenvironment",
abstract = "Prostate cancer cells move from their primary site of origin, interact with a distant microenvironment, grow, and thereby cause death. It had heretofore not been possible to selectively inhibit cancer cell motility. Our group has recently shown that inhibition of intracellular activation of Raf1 with the small-molecule therapeutic KBU2046 permits, for the first time, selective inhibition of cell motility. We hypothesized that simultaneous disruption of multiple distinct functions that drive progression of prostate cancer to induce death would result in advanced disease control. Using a murine orthotopic implantation model of human prostate cancer metastasis, we demonstrate that combined treatment with KBU2046 and docetaxel retains docetaxel's antitumor action, but provides improved inhibition of metastasis, compared with monotherapy. KBU2046 does not interfere with hormone therapy, inclusive of enzalutamide-mediated inhibition of androgen receptor (AR) function and cell growth inhibition, and inclusive of the ability of castration to inhibit LNCaP-AR cell outgrowth in mice. Cell movement is necessary for osteoclast-mediated bone degradation. KBU2046 inhibits Raf1 and its downstream activation of MEK1/2 and ERK1/2 in osteoclasts, inhibiting cytoskeleton rearrangement, resorptive cavity formation, and bone destruction in vitro, with improved effects observed when the bone microenvironment is chemically modified by pretreatment with zoledronic acid. Using a murine cardiac injection model of human prostate cancer bone destruction quantified by CT, KBU2046 plus zoledronic exhibit improved inhibitory efficacy, compared with monotherapy. The combined disruption of pathways that drive cell movement, interaction with bone, and growth constitutes a multifunctional targeting strategy that provides advanced disease control.",
author = "Limin Zhang and Abhinandan Pattanayak and Wenqi Li and Ko, {Hyun Kyung} and Graham Fowler and Ryan Gordon and Raymond Bergan",
year = "2020",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-19-0222",
language = "English (US)",
volume = "19",
pages = "39--51",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - A multifunctional therapy approach for cancer

T2 - Targeting Raf1- Mediated inhibition of cell motility, growth, and interaction with the microenvironment

AU - Zhang, Limin

AU - Pattanayak, Abhinandan

AU - Li, Wenqi

AU - Ko, Hyun Kyung

AU - Fowler, Graham

AU - Gordon, Ryan

AU - Bergan, Raymond

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Prostate cancer cells move from their primary site of origin, interact with a distant microenvironment, grow, and thereby cause death. It had heretofore not been possible to selectively inhibit cancer cell motility. Our group has recently shown that inhibition of intracellular activation of Raf1 with the small-molecule therapeutic KBU2046 permits, for the first time, selective inhibition of cell motility. We hypothesized that simultaneous disruption of multiple distinct functions that drive progression of prostate cancer to induce death would result in advanced disease control. Using a murine orthotopic implantation model of human prostate cancer metastasis, we demonstrate that combined treatment with KBU2046 and docetaxel retains docetaxel's antitumor action, but provides improved inhibition of metastasis, compared with monotherapy. KBU2046 does not interfere with hormone therapy, inclusive of enzalutamide-mediated inhibition of androgen receptor (AR) function and cell growth inhibition, and inclusive of the ability of castration to inhibit LNCaP-AR cell outgrowth in mice. Cell movement is necessary for osteoclast-mediated bone degradation. KBU2046 inhibits Raf1 and its downstream activation of MEK1/2 and ERK1/2 in osteoclasts, inhibiting cytoskeleton rearrangement, resorptive cavity formation, and bone destruction in vitro, with improved effects observed when the bone microenvironment is chemically modified by pretreatment with zoledronic acid. Using a murine cardiac injection model of human prostate cancer bone destruction quantified by CT, KBU2046 plus zoledronic exhibit improved inhibitory efficacy, compared with monotherapy. The combined disruption of pathways that drive cell movement, interaction with bone, and growth constitutes a multifunctional targeting strategy that provides advanced disease control.

AB - Prostate cancer cells move from their primary site of origin, interact with a distant microenvironment, grow, and thereby cause death. It had heretofore not been possible to selectively inhibit cancer cell motility. Our group has recently shown that inhibition of intracellular activation of Raf1 with the small-molecule therapeutic KBU2046 permits, for the first time, selective inhibition of cell motility. We hypothesized that simultaneous disruption of multiple distinct functions that drive progression of prostate cancer to induce death would result in advanced disease control. Using a murine orthotopic implantation model of human prostate cancer metastasis, we demonstrate that combined treatment with KBU2046 and docetaxel retains docetaxel's antitumor action, but provides improved inhibition of metastasis, compared with monotherapy. KBU2046 does not interfere with hormone therapy, inclusive of enzalutamide-mediated inhibition of androgen receptor (AR) function and cell growth inhibition, and inclusive of the ability of castration to inhibit LNCaP-AR cell outgrowth in mice. Cell movement is necessary for osteoclast-mediated bone degradation. KBU2046 inhibits Raf1 and its downstream activation of MEK1/2 and ERK1/2 in osteoclasts, inhibiting cytoskeleton rearrangement, resorptive cavity formation, and bone destruction in vitro, with improved effects observed when the bone microenvironment is chemically modified by pretreatment with zoledronic acid. Using a murine cardiac injection model of human prostate cancer bone destruction quantified by CT, KBU2046 plus zoledronic exhibit improved inhibitory efficacy, compared with monotherapy. The combined disruption of pathways that drive cell movement, interaction with bone, and growth constitutes a multifunctional targeting strategy that provides advanced disease control.

UR - http://www.scopus.com/inward/record.url?scp=85077668642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077668642&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-19-0222

DO - 10.1158/1535-7163.MCT-19-0222

M3 - Article

C2 - 31582531

AN - SCOPUS:85077668642

VL - 19

SP - 39

EP - 51

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 1

ER -